inSoma is pleased to announce the addition of Juliana Blum, Ph.D., to its Board of Directors. Dr. Blum is an expert in residence for NCBiotech and has spent over 20 years combining her scientific technical expertise with bioengineered regenerative tissue development. As a co-founder and former Executive Vice President of Corporate Development of Humacyte, a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at a commercial scale, Dr. Blum brings deep expertise in building a novel biotechnology platform and advancing the company through late-stage clinical development. She received her doctorate in Molecular Biology from Loyola University Chicago with a focus in cardiovascular gene therapy and her bachelors’ degree at Carthage College in Wisconsin.
inSoma Raises $2.5M in Seed Round
inSoma today announced it has raised $2.5 million in 2023 as part of a seed round. The raise builds on an initial pre-seed round raised in 2020, as well as the continued grant funding that inSoma has received from the NIH and NSF, and deepens the financial foundation from which to advance the development of a portfolio of injectable materials designed to mimic human tissue that can be used to rebuild a person’s tissue more safely and accurately, without the need for synthetic implants or fillers.
NSF Awards inSoma $1M Grant to Evaluate Fractomer’s Potential in Facial Fat Grafting
inSoma Bio has been awarded a highly competitive grant through the National Science Foundation (NSF) to explore the potential of Fractomer™️ in an additional soft tissue reconstruction application, facial fat grafting. This follow-on commercialization grant from the NSF further validates the broad potential of inSoma’s technology.